Use of a peptide

Abstract

The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.

1 . A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment i) an effective amount of metformin via oral administration and ii) an effective amount of an insulinotropic GLP-1 related peptide via injection or infusion, where said insulinotropic GLP-1 related peptide is selected from the group consisting of GLP-1 (7-37), GLP-1 (7-36) amide, an analogue of GLP-1 (7-37) and an analogue of GLP-1 (7-36) amide.  
     
     
         2 . The method of  claim 1 , wherein said insulinotropic GLP-1 related peptide is GLP-1 (7-36) amide.  
     
     
         3 . The method of  claim 1 , wherein said insulinotropic GLP-1 related peptide is an analogue of GLP-1 (7-37).  
     
     
         4 . The method of  claim 3 , wherein said analogue of GLP-1 {7-37) has one amino acid of GLP-1 (7-37) exchanged by another amino acid.  
     
     
         5 . A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment i) an effective amount of metformin via oral administration and ii) an effective amount of an insulinotropic GLP-1 related peptide via injection or infusion, where said insulinotroplc GLP-1 related peptide is selected from the group consisting of a functional derivative of GLP-1 (7-37), a functional derivative of GLP-1 (7-36) amide, a functional derivative of an analogue of GLP-1(7-37) and a functional derivative of an analogue of GLP-1 (7-36) amide.  
     
     
         6 . The method of  claim 5 , wherein said insulinotropic GLP-1 related peptide is a functional derivative of an analogue of GLP-1 (7-37).  
     
     
         7 . The method of  claim 6 , wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1(7-37) exchanged by another amino acid.  
     
     
         8 . A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment an amount of metformin and an amount of an insulinotropic peptide effective to treat said type 2 diabetes wherein the insulinotropic peptide is an insulinotropic GLP-1 related peptide selected from the group consisting of GLP-1 (7-37), GLP-1 (7-36) amide, an analogue of GLP-1 (7-37), an_analogue of GLP-1 (7-36) amide, a functional derivative of GLP-1 (7-37), a functional derivative of GLP-1 (7-36) amide, a functional derivative of an analogue of GLP-1 (7-37) and a functional derivative of an analogue of GLP-1 (7-36) amide.  
     
     
         9 . The method of  claim 8 , wherein the insulinotropic peptide is an insulinotropic GLP-1 related peptide selected from the group consisting of GLP-1 (7-37), GLP-1 (7-36) amide, [[or]] an analogue of GLP-1 (7-37) and an analogue of GLP-1 (7-36) amide.  
     
     
         10 . The method of  claim 8 , wherein the insulinotropic peptide is an insulinotropic GLP-1 related peptide selected from the group consisting of a functional derivative of GLP-1 (7-37), GLP-1 (7-36) amide, a functional derivative of an analogue of GLP-1 (7-37) and a functional derivative of an analogue of GLP-1 (7-36) amide.  
     
     
         11 . The method of  claim 9 , wherein said insulinotropic GLP-1 related peptide is GLP-1 (7-36) amide.  
     
     
         12 . The method of  claim 9 , wherein said insulinotropic GLP-1 related peptide is an analogue of GLP-1 (7-37).  
     
     
         13 . The method of  claim 12 , wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1 (7-37) exchanged by another amino acid.  
     
     
         14 . The method of  claim 10 , wherein said insulinotropic GLP-1 related peptide is a functional derivative of an analogue of GLP-1 (7-37).  
     
     
         15 . The method of  claim 14 , wherein said analogue of GLP-1 (7-37} has one amino acid of GLP-1(7-37) exchanged by another amino acid.  
     
     
         16 . The method of  claim 8 , wherein the insulinotropic peptide is administered to the subject via injection or infusion.  
     
     
         17 . The method of  claim 8 ,.wherein the metformin is administered to the subject orally.  
     
     
         18 . The method of  claim 8 , wherein said metformin is administered to the subject orally and said insulinotropic peptide is administered to the subject via injection or infusion.